[Effectiveness of Carboplatin plus Taxane Chemotherapy for Advanced or Recurrent Uterine Serous Carcinoma].
Uterine serous carcinoma(USC)is more aggressive compared to endometrioid adenocarcinoma, and often exhibits intraperitoneal spread, resulting in a poor prognosis. It is a rare subtype of uterine cancers, accounting for 5%of cases in Japan; therefore, optimal chemotherapy regimens for patients with advanced or recurrent disease have not been established. In the present study, we evaluated the safety and efficacy of carboplatin plus taxane chemotherapy for the treatment of patients withadvanced and recurrent USC. Patients withmeasurable advanced or recurrent USC who underwent carboplatin plus taxane chemotherapy, and in whom toxicities could be evaluated were eligible. Carboplatin(AUC 5)and paclitaxel(180mg/m2)were administered on day 1 of a 3-week cycle. Patients who required dose adjustments or carboplatin plus docetaxel because of age, comorbidities, or adverse events were included. Nine patients were included. The median patient age was 68 years(range, 45-81 years). Seven patients had Stage IV B disease(5 withperitoneal dissemination, 1 withbone metastasis, and 1 withmultiple lymphnode metastases, including metastasis at the mediastinal lymph nodes), and 2 patients had recurrent disease, both of whom developed postoperative peritoneal recurrence. One patient achieved a complete response(CR), and 6 achieved a partial response(PR), witha response rate(CR+PR)of 78%. Th e2 patients with recurrent disease achieved a PR. The median progression-free survival for the 7 responders was 9 months (range, 2-90 months). In terms of hematological toxicities, GradeB3 neutropenia occurred in 7 patients, but febrile neutropenia did not occur. One patient developed sepsis because of a subcutaneous central venous port infection. TC was a safe and efficacious regimen for patients with advanced or recurrent USC. To validate these findings, further investigations in a larger patient population are warranted.